Benefit of interferon β-1a on MSFC progression in secondary progressive MS
Abstract
Get full access to this article
View all available purchase options and get full access to this article.
Supplementary Material
References
Information & Authors
Information
Published In
Copyright
Publication History
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
- Diet-Induced Changes in Functional Disability among People with Multiple Sclerosis: A Secondary Pooled Analysis of Two Randomized Controlled Pilot Trials, Sclerosis, 2, 3, (156-165), (2024).https://doi.org/10.3390/sclerosis2030011
- An overview on disease modifying and symptomatic drug treatments for multiple sclerosis, Expert Review of Clinical Pharmacology, 17, 10, (901-921), (2024).https://doi.org/10.1080/17512433.2024.2410393
- Markers of secondary progression in multiple sclerosis, Multiple Sclerosis and Related Disorders, 91, (105881), (2024).https://doi.org/10.1016/j.msard.2024.105881
- Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges, The Lancet Neurology, 23, 3, (277-301), (2024).https://doi.org/10.1016/S1474-4422(24)00027-9
- Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis, Journal of Neurology, 271, 6, (3131-3141), (2024).https://doi.org/10.1007/s00415-024-12366-5
- Rituximab in secondary progressive multiple sclerosis: a meta‐analysis, Annals of Clinical and Translational Neurology, 11, 10, (2707-2718), (2024).https://doi.org/10.1002/acn3.52186
- Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis, Cochrane Database of Systematic Reviews, 2024, 9, (2024).https://doi.org/10.1002/14651858.CD015443.pub2
- Predictors of transition from relapsing‑remitting multiple sclerosis to secondary progressive, Medical alphabet, 14, (40-44), (2023).https://doi.org/10.33667/2078-5631-2023-14-40-44
- Technology-enabled assessments to enhance multiple sclerosis clinical care and research, Neurology Clinical Practice, 10, 3, (222-231), (2023)./doi/10.1212/CPJ.0000000000000710
- Identifying priority outcomes that influence selection of disease-modifying therapies in MS, Neurology Clinical Practice, 8, 3, (179-185), (2023)./doi/10.1212/CPJ.0000000000000449
- See more
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.